These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33662517)

  • 1. Next generation risk assessment of human exposure to anti-androgens using newly defined comparator compound values.
    van Tongeren TCA; Moxon TE; Dent MP; Li H; Carmichael PL; Rietjens IMCM
    Toxicol In Vitro; 2021 Jun; 73():105132. PubMed ID: 33662517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation risk assessment of human exposure to estrogens using safe comparator compound values based on in vitro bioactivity assays.
    van Tongeren TCA; Wang S; Carmichael PL; Rietjens IMCM; Li H
    Arch Toxicol; 2023 Jun; 97(6):1547-1575. PubMed ID: 37087486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Employing Dietary Comparators to Perform Risk Assessments for Anti-Androgens Without Using Animal Data.
    Dent MP; Li H; Carmichael PL; Martin FL
    Toxicol Sci; 2019 Feb; 167(2):375-384. PubMed ID: 30247711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Environmental concentrations of anti-androgenic pharmaceuticals do not impact sexual disruption in fish alone or in combination with steroid oestrogens.
    Green C; Brian J; Kanda R; Scholze M; Williams R; Jobling S
    Aquat Toxicol; 2015 Mar; 160():117-27. PubMed ID: 25630045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next Generation Risk Assessment of the Anti-Androgen Flutamide Including the Contribution of Its Active Metabolite Hydroxyflutamide.
    van Tongeren TCA; Carmichael PL; Rietjens IMCM; Li H
    Front Toxicol; 2022; 4():881235. PubMed ID: 35722059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
    Parent EE; Dence CS; Jenks C; Sharp TL; Welch MJ; Katzenellenbogen JA
    J Med Chem; 2007 Mar; 50(5):1028-40. PubMed ID: 17328524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization and prevalidation of the in vitro AR CALUX method to test androgenic and antiandrogenic activity of compounds.
    van der Burg B; Winter R; Man HY; Vangenechten C; Berckmans P; Weimer M; Witters H; van der Linden S
    Reprod Toxicol; 2010 Aug; 30(1):18-24. PubMed ID: 20438827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects.
    Lee S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2010 Dec; 32(14):2496-501. PubMed ID: 21353117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.
    Le HT; Schaldach CM; Firestone GL; Bjeldanes LF
    J Biol Chem; 2003 Jun; 278(23):21136-45. PubMed ID: 12665522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of animal toxicology studies with bicalutamide (ICI 176,334).
    Iswaran TJ; Imai M; Betton GR; Siddall RA
    J Toxicol Sci; 1997 May; 22(2):75-88. PubMed ID: 9198005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
    Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor antagonists and anti-prostate cancer activities of some synthesized steroidal candidates.
    Bahashwan SA; Al-Omar MA; Ezzeldin E; Abdalla MM; Fayed AA; Amr AG
    Chem Pharm Bull (Tokyo); 2011; 59(11):1363-8. PubMed ID: 22041072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative
    Scholze M; Taxvig C; Kortenkamp A; Boberg J; Christiansen S; Svingen T; Lauschke K; Frandsen H; Ermler S; Hermann SS; Pedersen M; Lykkeberg AK; Axelstad M; Vinggaard AM
    Environ Health Perspect; 2020 Nov; 128(11):117005. PubMed ID: 33236927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
    Kizu R; Okamura K; Toriba A; Mizokami A; Burnstein KL; Klinge CM; Hayakawa K
    Toxicol Sci; 2003 Dec; 76(2):299-309. PubMed ID: 12970580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation.
    Freyberger A; Witters H; Weimer M; Lofink W; Berckmans P; Ahr HJ
    Reprod Toxicol; 2010 Aug; 30(1):9-17. PubMed ID: 19836445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile development, characterization, and evaluation of novel bicalutamide loaded pH-sensitive mesoporous silica nanoparticles for enhanced prostate cancer therapy.
    Saroj S; Rajput SJ
    Drug Dev Ind Pharm; 2019 Apr; 45(4):532-547. PubMed ID: 30582382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
    Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.